How to buy Pharmaxis shares | A$0.091

Pharmaxis Ltd is a drug manufacturers—general business based in Australia. Pharmaxis shares (PXS) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.091 – a decrease of 1.09% over the previous week. Pharmaxis has a trailing 12-month revenue of around $12.6 million.

How to buy shares in Pharmaxis

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Pharmaxis . Find the share by name or ticker symbol: PXS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pharmaxis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $0.091, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Pharmaxis . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Pharmaxis 's share price?

Since the stock market crash in March caused by coronavirus, Pharmaxis 's share price has had significant negative movement.

Its last market close was $0.091, which is 17.27% down on its pre-crash value of $0.11 and 71.70% up on the lowest point reached during the March crash when the shares fell as low as $0.053.

If you had bought $1,000 worth of Pharmaxis shares at the start of February 2020, those shares would have been worth $469.57 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $791.30.

Pharmaxis share price

Use our graph to track the performance of PXS stocks over time.

Pharmaxis shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	AUDA$0.091
52-week range	AUDA$0.053 - AUDA$0.285
50-day moving average	AUDA$0.0861
200-day moving average	AUDA$0.0878
Target price	AUDA$0.52
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.053

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Pharmaxis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Pharmaxis Ltd by TradingView

Pharmaxis price performance over time

Historical closes compared with the close of A$0.091 on 2020-10-20

1 week (2020-10-10)	N/A
1 month (2020-09-21)	10.98%
3 months (2020-07-17)	5.81%
6 months (2020-04-17)	-6.19%

1 year (2019-10-18)	-55.61%
2 years (2018-10-19)	-69.15%
3 years (2017-10-19)	-65.66%
5 years (2015-10-19)	-59.56%

Pharmaxis financials

Revenue TTM	$12.6 million
Gross profit TTM	$11.2 million
Return on assets TTM	-22.53%
Return on equity TTM	-171.66%
Profit margin	-110.53%
Book value	0.004
Market capitalisation	$36 million

TTM: trailing 12 months

Pharmaxis share dividends

We're not expecting Pharmaxis to pay a dividend over the next 12 months.

Pharmaxis share price volatility

Over the last 12 months, Pharmaxis 's shares have ranged in value from as little as $0.053 up to $0.285. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pharmaxis 's is 0.508. This would suggest that Pharmaxis 's shares are less volatile than average (for this exchange).

Pharmaxis overview

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Frequently asked questions

• What percentage of Pharmaxis is owned by insiders or institutions?

  Currently 25.772% of Pharmaxis shares are held by insiders and 33.651% by institutions.

• When does the fiscal year end for Pharmaxis ?

  Pharmaxis 's fiscal year ends in June.

• Where is Pharmaxis based?

  Pharmaxis 's address is: 20 Rodborough Road, Frenchs Forest, NSW, Australia, 2086

• What is Pharmaxis 's ISIN number?

  Pharmaxis 's international securities identification number is: AU000000PXS5